Stock Report: Cornerstone Therapeutics Inc. (CRTX) Report Updated: May 13, 2013 | Print This Page

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of prescription pharmaceutical drugs for the hospital, niche respiratory, and related specialty markets. The company offers CUROSURF, a natural lung surfactant used for the treatment of respiratory distress syndrome in premature infants; and ZYFLO CR and ZYFLO, which are leukotriene synthesis inhibitor drugs used for the prevention and chronic treatment of asthma in adults and children. The company’s product pipeline also includes CRTX 080, a vasopressin receptor 2 antagonist lixivaptan used for the treatment of hyponatremia; CRTX 073, an anti-asthma product candidate used for the treatment of asthma; and CRTX 067, a cough/cold product candidate for the treatment of cough and cold. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was formerly known as Critical Therapeutics, Inc. and changed its name to Cornerstone Therapeutics Inc. as a result of its merger with Cornerstone BioPharma Holdings, Inc. in October 2008. Cornerstone Therapeutics Inc. was founded in 2000 and is headquartered in Cary, North Carolina. Cornerstone Therapeutics Inc operates as a subsidiary of Chiesi Farmaceutici S.p.A